1. Home
  2. APPN vs IBRX Comparison

APPN vs IBRX Comparison

Compare APPN & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APPN
  • IBRX
  • Stock Information
  • Founded
  • APPN 1999
  • IBRX 2014
  • Country
  • APPN United States
  • IBRX United States
  • Employees
  • APPN N/A
  • IBRX N/A
  • Industry
  • APPN Computer Software: Prepackaged Software
  • IBRX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • APPN Technology
  • IBRX Health Care
  • Exchange
  • APPN Nasdaq
  • IBRX Nasdaq
  • Market Cap
  • APPN 2.0B
  • IBRX 2.3B
  • IPO Year
  • APPN 2017
  • IBRX N/A
  • Fundamental
  • Price
  • APPN $29.11
  • IBRX $2.25
  • Analyst Decision
  • APPN Hold
  • IBRX Strong Buy
  • Analyst Count
  • APPN 6
  • IBRX 5
  • Target Price
  • APPN $34.40
  • IBRX $10.20
  • AVG Volume (30 Days)
  • APPN 1.2M
  • IBRX 8.7M
  • Earning Date
  • APPN 08-07-2025
  • IBRX 08-05-2025
  • Dividend Yield
  • APPN N/A
  • IBRX N/A
  • EPS Growth
  • APPN N/A
  • IBRX N/A
  • EPS
  • APPN N/A
  • IBRX N/A
  • Revenue
  • APPN $657,803,000.00
  • IBRX $56,600,000.00
  • Revenue This Year
  • APPN $12.72
  • IBRX $567.98
  • Revenue Next Year
  • APPN $10.04
  • IBRX $160.56
  • P/E Ratio
  • APPN N/A
  • IBRX N/A
  • Revenue Growth
  • APPN 13.67
  • IBRX 4227.22
  • 52 Week Low
  • APPN $24.00
  • IBRX $1.83
  • 52 Week High
  • APPN $43.33
  • IBRX $7.48
  • Technical
  • Relative Strength Index (RSI)
  • APPN 49.62
  • IBRX 38.56
  • Support Level
  • APPN $28.31
  • IBRX $2.17
  • Resistance Level
  • APPN $30.15
  • IBRX $2.94
  • Average True Range (ATR)
  • APPN 1.26
  • IBRX 0.15
  • MACD
  • APPN 0.11
  • IBRX -0.02
  • Stochastic Oscillator
  • APPN 42.33
  • IBRX 10.39

About APPN Appian Corporation

Appian Corp is a low-code enterprise platform-as-a-service company focusing on business process management. The company's Appian platform is an integrated automation platform providing tools for organizations to design, automate, and optimize end-to-end processes and complex business operations. Capabilities include case management, robotic process automation, artificial intelligence, data fabric, and process mining. The company also provides maintenance and support as well as consulting services and training related to its platform. The majority of its revenue is subscription-based with the remainder from services, with much of its subscription revenue being derived from its cloud-based platform. Geographically, the company derives maximum revenue from its business in the United States.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

Share on Social Networks: